Please use this identifier to cite or link to this item: https://doi.org/10.3390/cancers11081176
Title: Adaptive responses as mechanisms of resistance to braf inhibitors in melanoma
Authors: Saei, A.
Eichhorn, P.J.A. 
Keywords: Adaptive responses
BRAF
Melanoma
Resistance
Issue Date: 2019
Publisher: MDPI AG
Citation: Saei, A., Eichhorn, P.J.A. (2019). Adaptive responses as mechanisms of resistance to braf inhibitors in melanoma. Cancers 11 (8) : 1176. ScholarBank@NUS Repository. https://doi.org/10.3390/cancers11081176
Rights: Attribution 4.0 International
Abstract: The introduction of v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors in melanoma patients with BRAF (V600E) mutations has demonstrated significant clinical benefits. However, rarely do tumours regress completely. Frequently, the reason for this is that therapies targeting specific oncogenic mutations induce a number of intrinsic compensatory mechanisms, also known as adaptive responses or feedback loops, that enhance the pro-survival and pro-proliferative capacity of a proportion of the original tumour population, thereby resulting in tumour progression. In this review we will summarize the known adaptive responses that limit BRAF mutant therapy and discuss potential novel combinatorial therapies to overcome resistance. © 2019 by the authors.
Source Title: Cancers
URI: https://scholarbank.nus.edu.sg/handle/10635/212283
ISSN: 20726694
DOI: 10.3390/cancers11081176
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_cancers11081176.pdf2.53 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

11
checked on Sep 30, 2022

Page view(s)

59
checked on Sep 29, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons